Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

TYO:2395 Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	14,334	18,536	12,032	10,274	10,533	6,628
Short-Term Investments	-	-	-	336	-	368
Cash & Short-Term Investments	14,334	18,536	12,032	10,610	10,533	6,996
Cash Growth	23.88%	54.06%	13.40%	0.73%	50.56%	-3.97%
Receivables	7,001	7,132	6,513	5,722	4,695	3,499
Inventory	17,207	15,114	12,618	12,373	7,329	4,359
Other Current Assets	1,604	2,206	1,776	2,132	1,342	1,280
Total Current Assets	40,146	42,988	32,939	30,837	23,899	16,134
Property, Plant & Equipment	36,638	36,201	34,832	26,357	18,879	13,155
Long-Term Investments	19,083	22,159	20,469	15,926	12,404	8,645
Goodwill	1,746	1,762	1,884	1,934	1,438	-
Other Intangible Assets	383.54	360	219	225	261	212
Long-Term Deferred Tax Assets	-	1,551	2,036	989	325	1,129
Other Long-Term Assets	2,212	2	2	2	2	1
Total Assets	100,209	105,055	92,416	76,302	57,242	39,312

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	263.59	406	460	460	419	64
Short-Term Debt	19,570	19,669	11,777	7,826	8,923	2,942
Current Income Taxes Payable	82.36	966	2,217	1,701	603	743
Other Current Liabilities	19,578	18,284	14,802	13,580	11,066	9,624
Total Current Liabilities	39,494	39,325	29,256	23,567	21,011	13,373
Long-Term Debt	17,286	21,121	22,271	18,147	9,480	5,809
Long-Term Leases	727.4	468	425	212	357	385
Long-Term Deferred Tax Liabilities	-	481	235	84	-	-
Other Long-Term Liabilities	435.29	172	145	133	36	22
Total Liabilities	57,943	61,567	52,332	42,143	30,884	19,589

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	9,679	9,679	9,679	9,679	9,679	9,679
Additional Paid-In Capital	2,426	2,398	2,358	2,358	2,306	2,306
Retained Earnings	22,334	22,572	20,087	17,215	13,766	10,196
Comprehensive Income & Other	7,293	8,471	7,898	4,861	460	-2,620
Total Common Equity	41,732	43,120	40,022	34,113	26,211	19,561
Minority Interest	534.14	368	62	46	147	162
Shareholders' Equity	42,266	43,488	40,084	34,159	26,358	19,723
Total Liabilities & Equity	100,209	105,055	92,416	76,302	57,242	39,312

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	37,584	41,258	34,473	26,185	18,760	9,136
Net Cash (Debt)	-23,249	-22,722	-22,441	-15,575	-8,227	-2,140
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-558.45	-545.80	-539.05	-374.12	-197.62	-51.40
Filing Date Shares Outstanding	41.63	41.63	41.63	41.63	41.63	41.63
Total Common Shares Outstanding	41.63	41.63	41.63	41.63	41.63	41.63
Working Capital	652.03	3,663	3,683	7,270	2,888	2,761
Book Value Per Share	1002.40	1035.75	961.33	819.40	629.59	469.85
Tangible Book Value	39,603	40,998	37,919	31,954	24,512	19,349
Tangible Book Value Per Share	951.26	984.78	910.82	767.54	588.78	464.76
Order Backlog	-	41,988	35,690	34,404	29,249	19,724

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error